Faricimab

Adult: Initially, 6 mg (0.05 mL) once every 4 weeks (approx every 28 days) for the 1st 4 doses. Assess disease activity 20 and/or 24 weeks after treatment initiation and individualise dosing frequency based on anatomic and/or visual outcomes. In patients without disease activity: 6 mg once every 16 weeks. In patients with disease activity: 6 mg once every 8 or 12 weeks. Discontinue treatment if visual and/or anatomic outcomes indicate that the patient is not benefitting from continued treatment.

Adult: 6 mg (0.05 mL) once every 4 weeks (approx every 28 days) for the 1st 4 doses. Subsequent doses may be individualised using a treat-and-extend approach based on anatomic and/or visual outcomes. The treatment interval may be extended from every 4 to every 16 weeks, with extensions in increments of up to 4 weeks or reductions of up to 8-week intervals based on anatomic and/or visual outcomes. Alternatively, 6 mg (0.05 mL) once every 4 weeks for the 1st 6 doses, followed by 6 mg once every 8 weeks over the next 28 weeks. Discontinue treatment if visual and/or anatomic outcomes indicate that the patient is not benefitting from continued treatment.